Efficacy of co-medications in patients with alcoholic liver disease

Background: Alcoholic liver disease (ALD) is still increasing and leads to acute liver injury but also liver cirrhosis and subsequent complications such as liver failure or hepatocellular carcinoma (HCC). As most patients fail to achieve alcohol abstinence, it is essential to identify alternative tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Itzel, Timo (Author) , Falconer, Thomas (Author) , Roig, Ana (Author) , Daza Barragán, Jimmy Andres (Author) , Park, Jimyung (Author) , Cheong, Jae Youn (Author) , Park, Rae Woong (Author) , Wiest, Isabella (Author) , Ebert, Matthias (Author) , Hripcsak, George (Author) , Teufel, Andreas (Author)
Format: Article (Journal)
Language:English
Published: September 2023
In: Digestive diseases
Year: 2023, Volume: 41, Issue: 5, Pages: 780-788
ISSN:1421-9875
DOI:10.1159/000529914
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000529914
Verlag, lizenzpflichtig, Volltext: https://karger.com/ddi/article/41/5/780/853508/Efficacy-of-Co-Medications-in-Patients-with
Get full text
Author Notes:Timo Itzel, Thomas Falconer, Ana Roig, Jimmy Daza, Jimyung Park, Jae Youn Cheong, Rae Woong Park, Isabella Wiest, Matthias P. Ebert, George Hripcsak, Andreas Teufel
Description
Summary:Background: Alcoholic liver disease (ALD) is still increasing and leads to acute liver injury but also liver cirrhosis and subsequent complications such as liver failure or hepatocellular carcinoma (HCC). As most patients fail to achieve alcohol abstinence, it is essential to identify alternative treatment options in order to improve the outcome of ALD patients. Methods: Evaluating two large cohorts of patients with ALD from the USA and Korea with a total of 12,006 patients, we investigated the effect on survival of aspirin, metformin, metoprolol, dopamine, and dobutamine drugs in patients with ALD between 2000 and 2020. Patient data were obtained through the “The Observational Health Data Sciences and Informatics consortium,” an open-source, multi-stakeholder, and interdisciplinary collaborative effort. Results: The use of aspirin (p = 0.000, p = 0.000), metoprolol (p = 0.002, p = 0.000), and metformin (p = 0.000, p = 0.000) confers a survival benefit for both AUSOM- and NY-treated cohorts. Need of catecholamines dobutamine (p = 0.000, p = 0.000) and dopamine (p = 0.000, p = 0.000) was strongly indicative of poor survival. β-Blocker treatment with metoprolol (p = 0.128, p = 0.196) or carvedilol (p = 0.520, p = 0.679) was not shown to be protective in any of the female subgroups. Conclusion: Overall, our data fill a large gap in long-term, real-world data on patients with ALD, confirming an impact of metformin, acetylsalicylic acid, and β-blockers on ALD patient’s survival. However, gender and ethnic background lead to diverse efficacy in those patients.
Item Description:Online veröffentlicht: 26. Juni 2023
Gesehen am 10.09.2024
Physical Description:Online Resource
ISSN:1421-9875
DOI:10.1159/000529914